Tempus AI (NASDAQ: TEM) is set to present nine abstracts at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas, from November 6-10, 2024, showcasing advancements in AI-driven precision medicine. Among the highlights are the validation of a novel multi-omic algorithm for predicting immune checkpoint inhibitor (ICI) treatment outcomes and a cost-effectiveness analysis of molecular biomarkers combined with CT imaging for treatment response monitoring. These studies underscore the potential of AI and data-driven approaches to refine cancer treatment strategies and improve patient outcomes.
Immune Profile Score (IPS) Algorithm Validation
One of the key presentations will focus on the clinical validation of a novel multi-omic algorithm designed to predict patient outcomes following treatment with immune checkpoint inhibitors (ICIs). The algorithm, known as the Immune Profile Score (IPS), integrates DNA and RNA sequencing data to stratify patients based on their likelihood of response to ICI therapy. Researchers utilized a de-identified pan-cancer cohort from the Tempus multimodal real-world database to develop and validate the IPS algorithm, leveraging Tempus xT (DNA sequencing) and xR (RNA sequencing) technologies. The study demonstrated that IPS status could effectively stratify patient cohorts and prognosticate ICI-treatment response, potentially allowing for more informed treatment decisions.
Cost-Effectiveness of Molecular Biomarkers and CT Imaging
Another significant study analyzed the cost-effectiveness of incorporating molecular biomarkers with Computed Tomography (CT) imaging for treatment response monitoring (TRM) in advanced cancer patients. The research team modeled the impact of CT imaging patterns on the clinical utility and cost-effectiveness of a molecular biomarker for TRM compared to imaging alone. Analyzing real-world imaging patterns from a cohort of 4,147 advanced cancer patients treated with ICIs across five solid tumor types, the study revealed considerable variability in CT scan intervals between different cancer types and treatments. By incorporating these patterns into a microsimulation model, the team found that using the molecular biomarker in conjunction with CT imaging resulted in substantial cost savings and reduced inappropriate therapy compared to relying solely on imaging. The most pronounced benefits were observed in small cell lung cancer (SCLC) patients undergoing ICI-chemotherapy.
Clinical and Economic Implications
"Presenting our latest research is a vital opportunity to showcase the advancements Tempus is making in harnessing the power of data and AI to drive immunotherapy innovation," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are committed to working with the oncology community to share insights that can accelerate the development of more effective, personalized therapies and contribute to the improvement of outcomes for patients."
The findings from these studies suggest that integrating advanced AI algorithms and molecular biomarkers into cancer treatment monitoring can lead to more efficient resource allocation and improved patient care. The ability to predict immunotherapy outcomes with greater accuracy and reduce unnecessary imaging could have a significant impact on healthcare costs and clinical practice guidelines.
